Long-Acting Reversible Contraception: The Contraceptive CHOICE Project

Jeffrey F. Peipert, M.D., Ph.D.

Vice Chair of Clinical Research
Robert J. Terry Professor

Department of Obstetrics & Gynecology
Washington University in St. Louis
School of Medicine
March 15, 2016



FINANCIAL CONFLICTS

Research Grant Support Bayer, Merck, Teva

Advisory Boards
Perrigo, Teva




OBJECTIVES

- Describe the contraceptive choices of participants in the Contraceptive CHOICE Project
- Provide the continuation rates of contraceptive options
- Provide evidence for compliance/adherence and contraceptive failure rates



U.S. Percent of Pregnancies Unintended is High






Disparities by Race & Ethnicity Persist Across Income Groups





Typical Use - First Year Failure Rates



^{*}Estimates in lieu of actual data





Long-Acting Reversible Contraception

There is a need for effective contraceptive methods that are

forgettable












Contraceptive Cohort Study


- Remove financial barriers to most effective long-term reversible methods
- Recruit 10,000 participants over 4 years
 - No-cost contraception
 - Participant choice
 - 2-3 years follow-up
 - Assess continuation, satisfaction
 - Population outcomes:
 - Unintended/teen pregnancy





Long-Acting Reversible Contraception







LNG-IUS

- 99% effective
- 20 mcg levonorgestrel/day
- Up to 5 years

Copper T IUD

- 99% effective
- Copper ions
- Up to 10 years

Subdermal Implant

- 99% effective
- 60 mcg etonogestrel/day
- Up to 3 years





CHOICE: Inclusion Criteria

- 14-45 years
- Primary residency in STL City or Country
- Sexually active with male partner (or soon to be)
- Does not desire pregnancy during next 12 months
 - Desires reversible contraception
- Willing to try a new contraceptive method



Contraceptive CHOICE Project: Study Details

ELIGIBLE

Tiered
Contraceptive
Counseling



LNG-IUS
Cu-IUD
Implant
DMPA
Pills
Patch
Ring
Other





Baseline Characteristics

Age (years)	N	%
14-17	485	2,033 5.2
18-20	1548	2,033 16.7
21-25	3559	38.5
26-35	3029	32.7
36-45	635	6.9
Race		
Black	4660	50.6
White	3861	41.9
Other	693	7.5



Baseline Characteristics (N=9,256)

SES	n	%
Public assistance	3442	37.2
Trouble meeting basic needs	3639	39.3
Insurance	n	%
Insurance None	n 3782	% 41.1

Baseline Characteristics

Parity	N	%
0	4375	47.3
1-2	3885	50.0
3+	996	10.7
Unintended pregnancy	5857	63.2
History of STI	3746	40.5




LARC Acceptance

LNG-IUS	46.0
CuT380A	11.9 ~ 75 %
Implant	16.9
DMPA	6.9
Pills	9.4
Ring	7.0
Patch	1.8
Other	<1.0



Choice of LARC Methods in Adolescents





NEJM CHOICE Publication

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Effectiveness of Long-Acting Reversible Contraception

Brooke Winner, M.D., Jeffrey F. Peipert, M.D., Ph.D., Qiuhong Zhao, M.S., Christina Buckel, M.S.W., Tessa Madden, M.D., M.P.H., Jenifer E. Allsworth, Ph.D., and Gina M. Secura, Ph.D., M.P.H.




Unintended Pregnancy by Contraceptive Method



HR_{adi} = 22.3 (95% CI 14.0, 35.4) TWENTY-FOLD DIFFERENCE!



Method Failure by Age



 $HR_{adj} = 1.9;$ 95% CI 1.2, 2.8



12- & 24-Month Continuation: Overall Cohort



Method	12-Month (%)	24-Month (%)
LNG-IUS	87.5	78.9
Copper IUD	84.1	77.3
Implant	83.3	68.5
Any LARC	86.2	76.6
DMPA	56.2	38.0
OCPs	55.0	43.5
Ring	54.2	41.1
Patch	49.5	39.9
Non-LARC	54.7	40.9



12-Month Satisfaction*: Overall Cohort & By Age




Method	Overall (%)	14-19 (%)	20-45 (%)
LNG- IUS	83.1	77%	84%
Copper IUD	80.2	72%	81%
Implant	77.0	74%	78%
Any LARC	81.2	75%	82%
DMPA	50.1	43%	52%
Pills	49.3	46%	50%
Ring	49.7	31%	52%
Patch	37.2	35%	38%
Non-LARC	48.8	42%	50%



*Very or somewhat satisfied combined


"Intent to Use" versus "As Used" Where does DMPA fit?





"GAP" Analysis: Multivariable Risk Factors for Unintended Pregnancy

<u>FACTOR</u>	HR _{adj}
4+ College	0.5
< 20 years	1.3
Low SES	1.3
Prior UIP	2.0
GAP	14.0



NEJM CHOICE Publication

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Provision of No-Cost, Long-Acting Contraception and Teenage Pregnancy

Gina M. Secura, Ph.D., M.P.H., Tessa Madden, M.D., M.P.H., Colleen McNicholas, D.O., Jennifer Mullersman, B.S.N., Christina M. Buckel, M.S.W., Qiuhong Zhao, M.S., and Jeffrey F. Peipert, M.D., Ph.D.




Teen Outcomes: CHOICE Compared to U.S.

	CHOICE Annual Rate*	2008 U.S. Rate*	Reduction
Pregnancy among sexually active teens	34.0	158.5	64%
Birth	19.4	94.0	63%
Abortion	9.7	41.5	65%
*All rates per 1,000 teens 15-19 years			



NATIONAL LEADERS IN MEDICINE

Pregnancy Rates: Sexually Experienced U.S. Teens Compared to CHOICE Stratified by Race





Take-Home Messages

- WHY such a high uptake of LARC?
 - EFFECTIVENESS: key attribute
 - Forgettable: not dependent on adherence
- HIGH continuation rates for long-acting methods, but NOT DMPA, pills, patch or ring
 - Why? Speculation.....
- Application to Microbicides:
 - Longer-acting methods are best (?)



Thank you





